PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31123394-0 2019 Glibenclamide alleviates inflammation in oleic acid model of acute lung injury through NLRP3 inflammasome signaling pathway. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 87-92 32522579-0 2020 Glibenclamide attenuates 2,5-hexanedione-induced neurotoxicity in the spinal cord of rats through mitigation of NLRP3 inflammasome activation, neuroinflammation and oxidative stress. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 112-117 32522579-5 2020 Glibenclamide, a sulfonylurea inhibitor of NLRP3 inflammasome, reduced HD-induced NLRP3 inflammasome activation, which was associated with mitigated gasdermin D (GSDMD) cleavage, neurofilament protein L (NF-L) reduction and demyelination as well as axon degeneration in the spinal cord of rats. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 43-48 32522579-5 2020 Glibenclamide, a sulfonylurea inhibitor of NLRP3 inflammasome, reduced HD-induced NLRP3 inflammasome activation, which was associated with mitigated gasdermin D (GSDMD) cleavage, neurofilament protein L (NF-L) reduction and demyelination as well as axon degeneration in the spinal cord of rats. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 82-87 32522579-6 2020 Subsequently, we found that inhibition of NLRP3 inflammasome by glibenclamide suppressed microglial activation and M1 polarization and simultaneously recovered M2 polarization in HD-intoxicated rats. Glyburide 64-77 NLR family, pyrin domain containing 3 Rattus norvegicus 42-47 32522579-9 2020 Inhibition of NLRP3 inflammasome by glibenclamide might a potential avenue to combat n-hexane-induced neuropathy. Glyburide 36-49 NLR family, pyrin domain containing 3 Rattus norvegicus 14-19 32153049-3 2020 NLRP3 inflammasomes have been linked to IL-1beta expression, but it is currently unclear whether glyburide, the inhibiter of NLRP3 inflammasome, suppresses occlusal trauma in rats. Glyburide 97-106 NLR family, pyrin domain containing 3 Rattus norvegicus 125-130 32153049-6 2020 In the trauma + glyburide group, the NLRP3 inhibitor glyburide was administered orally every 24 hours from 1 day before induction of occlusal trauma. Glyburide 53-62 NLR family, pyrin domain containing 3 Rattus norvegicus 37-42 31761320-0 2020 Diethylnitrosamine and thioacetamide-induced hepatic damage and early carcinogenesis in rats: Role of Nrf2 activator dimethyl fumarate and NLRP3 inhibitor glibenclamide. Glyburide 155-168 NLR family, pyrin domain containing 3 Rattus norvegicus 139-144 31761320-3 2020 Glibenclamide (GLB), a sulphonylurea drug used to treat type II diabetes, possesses anti-inflammatory properties and inhibits NLRP3 inflammasomes. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 126-131 31761320-3 2020 Glibenclamide (GLB), a sulphonylurea drug used to treat type II diabetes, possesses anti-inflammatory properties and inhibits NLRP3 inflammasomes. Glyburide 15-18 NLR family, pyrin domain containing 3 Rattus norvegicus 126-131 31761320-6 2020 DMF and GLB intervention significantly ameliorated the DEN + TAA-induced alterations in the antioxidant (Nrf2, HO-1, SOD-1, catalase), inflammatory (NF-kappaB, NLRP3, ASC, caspase-1), fibrogenic (TGF-beta1, collagen) and regenerative proliferative stress (GST-p, HGF, c-MET, TGFalpha, EGF, AFP) markers. Glyburide 8-11 NLR family, pyrin domain containing 3 Rattus norvegicus 160-165 35141913-14 2022 Glyburide, an NOD-like receptor pyrin domain containing protein 3 (NLRP3)inhibitor, reduced the expression of pyroptosis markers induced by occlusal trauma with periodontitis and reversed bone resorption. Glyburide 0-9 NLR family, pyrin domain containing 3 Rattus norvegicus 67-72 32860822-4 2020 Interestingly, glybenclamide, a widely used inhibitor of NLRP3 inflammasome, significantly reduced NLRP3 inflammasome activation, which was associated with decreased GSDMD cleavage and axon degeneration as well as improved motor performance of HD-intoxicated rats. Glyburide 15-28 NLR family, pyrin domain containing 3 Rattus norvegicus 57-62 32860822-4 2020 Interestingly, glybenclamide, a widely used inhibitor of NLRP3 inflammasome, significantly reduced NLRP3 inflammasome activation, which was associated with decreased GSDMD cleavage and axon degeneration as well as improved motor performance of HD-intoxicated rats. Glyburide 15-28 NLR family, pyrin domain containing 3 Rattus norvegicus 99-104 32860822-5 2020 Subsequently, we found that inhibition of NLRP3 inflammasome by glybenclamide attenuated macrophage infiltration, activation and M1 polarization in sciatic nerves of HD-intoxicated rats. Glyburide 64-77 NLR family, pyrin domain containing 3 Rattus norvegicus 42-47 31834465-0 2020 NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway. Glyburide 16-29 NLR family, pyrin domain containing 3 Rattus norvegicus 0-5 31834465-3 2020 Glibenclamide (GLB) is a potent NLRP3 inflammasome inhibitor and possesses anti-inflammatory and anti-oxidant properties. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 32-37 31834465-3 2020 Glibenclamide (GLB) is a potent NLRP3 inflammasome inhibitor and possesses anti-inflammatory and anti-oxidant properties. Glyburide 15-18 NLR family, pyrin domain containing 3 Rattus norvegicus 32-37 31834465-10 2020 Immunohistochemical and immunoblotting findings showed that GLB improved the hepatic expressions of inflammatory markers (NLRP3, ASC, caspase-1, IL-1beta, NF-kappaB), anti-oxidant markers (SOD, catalase) and insulin signalling markers (p-AKT, p-GSK-3beta, p-IRS). Glyburide 60-63 NLR family, pyrin domain containing 3 Rattus norvegicus 122-127 31197747-11 2019 Glyburide also diminished the levels of the NLRP3 subunit and caspase-1, but only in the diabetic cultures. Glyburide 0-9 NLR family, pyrin domain containing 3 Rattus norvegicus 44-49 31946797-0 2019 Neuroprotection of Glibenclamide against Brain Injury after Cardiac Arrest via Modulation of NLRP3 Inflammasome. Glyburide 19-32 NLR family, pyrin domain containing 3 Rattus norvegicus 93-98 31946797-9 2019 Furthermore, on the molecular basis, the NLRP3 inflammasome was strongly activated in the hippocampal CA1 area 3 days after CA in control rats, which was suppressed with GBC treatment. Glyburide 170-173 NLR family, pyrin domain containing 3 Rattus norvegicus 41-46 31123394-14 2019 Pretreatment with glibenclamide partly inhibited the increase in NLRP3, caspase-1 and IL-1beta expression induced by OA, simultaneously attenuated the lung injury. Glyburide 18-31 NLR family, pyrin domain containing 3 Rattus norvegicus 65-70 31123394-17 2019 Glibenclamide can alleviate this kind of ALI by inhibiting rather the NLRP3/caspase-1/IL-1beta signaling pathway than the levels of FFAs or TLR4 pathway. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 70-75 30066023-0 2018 Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 100-105 30353742-0 2019 Bladder decompensation and reduction in nerve density in a rat model of chronic bladder outlet obstruction are attenuated with the NLRP3 inhibitor glyburide. Glyburide 147-156 NLR family, pyrin domain containing 3 Rattus norvegicus 131-136 30066023-12 2018 GLB treatment significantly downregulated the expressions of TGF-beta1, alpha-SMA, NLRP3, ASC, caspase-1, and IL-1beta, and upregulated MMP-2 and catalase against TAA-induced liver damage. Glyburide 0-3 NLR family, pyrin domain containing 3 Rattus norvegicus 83-88 29802529-6 2018 Inhibition of NLRP3 by glyburide strongly suppressed the expression of NLRP3 inflammasome proteins and IL-1beta, and markedly reduced brain tissue damage. Glyburide 23-32 NLR family, pyrin domain containing 3 Rattus norvegicus 14-19 29802529-6 2018 Inhibition of NLRP3 by glyburide strongly suppressed the expression of NLRP3 inflammasome proteins and IL-1beta, and markedly reduced brain tissue damage. Glyburide 23-32 NLR family, pyrin domain containing 3 Rattus norvegicus 71-76 28984997-4 2018 METHODS: There were five groups of rats: (i) Control (no surgery); (ii) Sham-operated; (iii) BOO rats given vehicle; (iv) BOO rats given the NLRP3 inhibitor glyburide; and (v) BOO rats given the IL-1 receptor antagonist anakinra. Glyburide 157-166 NLR family, pyrin domain containing 3 Rattus norvegicus 141-146 28984997-12 2018 The decrease in nerve density was blocked by glyburide or anakinra, clearly implicating the NLRP3 pathway in denervation. Glyburide 45-54 NLR family, pyrin domain containing 3 Rattus norvegicus 92-97 28961497-4 2017 In the present study, PC12 neuronal cells were exposed to oxygen-glucose deprivation (OGD), exogenous irisin (12.5, 25, 50nmol/L) or NLRP3 inhibitor glyburide (50, 100, 200mumol/L) were used as an intervention reagent, NLRP3 was over-expressed or suppressed by transfection with a NLRP3 expressing vector or NLRP3-specifc siRNA, respectively. Glyburide 149-158 NLR family, pyrin domain containing 3 Rattus norvegicus 133-138 27066297-5 2016 Glyburide (a NLRP3 inhibitor) or vehicle was administered orally prior to and after injection. Glyburide 0-9 NLR family, pyrin domain containing 3 Rattus norvegicus 13-18 26707508-7 2016 Rats with bladder outlet obstruction were given vehicle (10% ethanol) or 10 mg/kg glyburide (a NLRP3 inhibitor) orally daily for 12 days. Glyburide 82-91 NLR family, pyrin domain containing 3 Rattus norvegicus 95-100 25338942-5 2015 Moreover, rats were pretreated with 10, 30, and 50 mg/kg NLRP3 inflammasome blocker glybenclamide, respectively, 1 h before PQ exposure. Glyburide 84-97 NLR family, pyrin domain containing 3 Rattus norvegicus 57-62 25338942-8 2015 NLRP3 inflammasome blocker glybenclamide pretreatment attenuated lung edema, inhibited the NLRP3, ASC, and caspase-1 activation, and reduced IL-1beta and IL-18 levels in BALF. Glyburide 27-40 NLR family, pyrin domain containing 3 Rattus norvegicus 0-5 25338942-8 2015 NLRP3 inflammasome blocker glybenclamide pretreatment attenuated lung edema, inhibited the NLRP3, ASC, and caspase-1 activation, and reduced IL-1beta and IL-18 levels in BALF. Glyburide 27-40 NLR family, pyrin domain containing 3 Rattus norvegicus 91-96 24291534-3 2014 NOD-like receptor protein-3 (NLRP-3) is pro-inflammatory in the kidney; glibenclamide inhibits production of NLRP-3. Glyburide 72-85 NLR family, pyrin domain containing 3 Rattus norvegicus 0-27 24291534-3 2014 NOD-like receptor protein-3 (NLRP-3) is pro-inflammatory in the kidney; glibenclamide inhibits production of NLRP-3. Glyburide 72-85 NLR family, pyrin domain containing 3 Rattus norvegicus 109-115 24291534-8 2014 Glibenclamide decreased infiltration of chronic inflammatory cells, fibrosis, tubular damage and expression of HO-1, TNF-alpha and NLRP-3 in the kidney. Glyburide 0-13 NLR family, pyrin domain containing 3 Rattus norvegicus 131-137